October 17, 2011 -- Samantha Du, PhD, has quietly stepped back from her duties as CEO of Hutchison MediPharma and Chief Scientific Officer of its parent, Hutchison Chi-Med. She apparently will remain involved with Hutchison as she has some time to evaluate her next career move. Dr. Du is a true pioneer in China pharma, having convinced Hutchison Whampoa to launch a drug development company in the early 2000s when most believed there was no novel drug development in China. She proved everyone wrong, bringing several novel entities to the clinic. More details....
Stock Symbol: (AIM: CHM)
